Quadrivalent meningitis receives notice of acceptance of clinical application_Chengda biotechnology

中 / EN



中文 EN

返回

Home page

News dynamics 

Company News Industry News

Voice of the Party 

Party building work Trade Union Activities

Quadrivalent meningitis receives notice of acceptance of clinical application

Category:

Release date: 2022-03-17 17:32:46.000

Visits:

Si Qing Activity 1: Collection of Works and Special Works for the 20th Anniversary of the Company's Essay and Photography Contest Previous

Chengda Bio: Fifteen-valent HPV vaccine clinical trial approved. Next

Recommended News

Phase I clinical trial of the fifteen-valent HPV vaccine developed by Chengda Bio was officially launched.

Chengda Biology's First "King Hegemony" Laws and Regulations Knowledge Contest Successfully Ends

The fragrance of floral arts will bloom forever

China Vaccine Industry Association Rabies Prevention and Control 2023

The book scent keeps the beginning heart and shares the good things together.

The company's party committee organized outstanding collectives and individuals to go to Dalian red base to "recharge and store energy"

Picture Name

Follow us

Telephone

Marketing Center

International Trade

Medical Consultation

400-101-1359 （weekday）

Address

No.1, XinFang Street, Hunnan New District, Shenyang City

辽ICP备15013481号-1

Video Number

Video Number

TikTok

TikTok

WeChat

WeChat

Weibo

123456789

12456789